What the company does
GFC Life Science develops specialty ingredients for cosmetics, including active compounds derived from skin microbiome research and exosome extraction technology, and supplies them to domestic and international cosmetics brands.
It also runs a clinical-testing division that provides efficacy and claims-substantiation testing services to cosmetics manufacturers and marketers, a service required under Korean cosmetics regulations. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: materials supply and clinical services.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2024US$12.2M
- FY2025US$12.8M
Operating profit
- FY2024US$1.2M
- FY2025US$279.9K
Net income
- FY2024−US$4.3M
- FY2025US$402.5K
Key ratios (FY2025)
Why it matters · Context, not a recommendation
Korean cosmetics law requires brands to hold certified test data before making efficacy claims in advertising, which underpins the demand for GFC's clinical-testing division.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?